The estimated Net Worth of Frank Mccormick is at least 29.8 百万$ dollars as of 26 December 2023. Frank Mccormick owns over 100,000 units of BridgeBio Pharma Inc stock worth over 17,569,015$ and over the last 21 years he sold BBIO stock worth over 12,237,000$. In addition, he makes 0$ as Chairman of Oncology at BridgeBio Pharma Inc.
Sign up
Frank Mccormick BBIO stock SEC Form 4 insiders trading
Frank has made over 3 trades of the BridgeBio Pharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 100,000 units of BBIO stock worth 4,206,000$ on 26 December 2023.
The largest trade he's ever made was selling 100,000 units of BridgeBio Pharma Inc stock on 26 December 2023 worth over 4,206,000$. On average, Frank trades about 11,538 units every 56 days since 2003. As of 26 December 2023 he still owns at least 627,689 units of BridgeBio Pharma Inc stock.
You can see the complete history of Frank Mccormick stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Frank Mccormick biography
Dr. Frank Mccormick Ph.D. serves as Chairman of Oncology of the Company. Dr. McCormick has held the positions of Director the UCSF Helen Diller Family Comprehensive Cancer Center, a multidisciplinary research and medical care organization and served as Associate Dean of the UCSF School of Medicine from 1997 to 2014. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several biotechnology firms, including Cetus Corporation as Director of Molecular Biology from 1981 to 1990 and Vice President of Research from 1990 to 1991, and Chiron Corporation as Vice President of Research from 1991 to 1992. In 1992, Dr. McCormick founded Onyx Pharmaceuticals and served as its Chief Scientific Officer until 1996. Dr. McCormick received his B.Sc. in biochemistry from the University of Birmingham, and his Ph.D. in biochemistry from the University of Cambridge and held postdoctoral fellowships in the U.S. at the State University of New York at Stony Brook and in London at the Imperial Cancer Research Fund. Dr. McCormick is a Fellow of the Royal Society, an institution dedicated to science, since 1996, a member of the National Academy of Sciences since 2014 and has served as President, 2012 to 2013, for the American Association for Cancer Research. Since 2013, Dr. McCormick has led the National Cancer Institute’s Ras Initiative at the Frederick National Laboratories for Cancer Research overseeing the national effort to develop therapies against Ras-driven cancers.
How old is Frank Mccormick?
Frank Mccormick is 69, he's been the Chairman of Oncology of BridgeBio Pharma Inc since 2019. There are 2 older and 20 younger executives at BridgeBio Pharma Inc. The oldest executive at BridgeBio Pharma Inc is Dr. Charles J. Homcy M.D., 73, who is the Chairman of Pharmaceuticals & Lead Director.
What's Frank Mccormick's mailing address?
Frank's mailing address filed with the SEC is C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO, CA, 94304.
Insiders trading at BridgeBio Pharma Inc
Over the last 5 years, insiders at BridgeBio Pharma Inc have traded over 409,396,563$ worth of BridgeBio Pharma Inc stock and bought 12,280,644 units worth 209,241,115$ . The most active insiders traders include Global Investors Lp Viking ...、Andrew Lo、Genetic Disorder L.P.Kkr Ge.... On average, BridgeBio Pharma Inc executives and independent directors trade stock every 12 days with the average trade being worth of 4,173,197$. The most recent stock trade was executed by Neil Kumar on 16 August 2024, trading 55,537 units of BBIO stock currently worth 1,554,481$.
What does BridgeBio Pharma Inc do?
we focus on accelerating and maximizing value in early-stage, genetic disease assets by applying our management expertise and proprietary platform. our team picks the right assets based on our systematic mapping of the genetic disease landscape, and develops those assets with the right approach, supporting r&d with expert capabilities and placing them in a value maximizing corporate structure.
What does BridgeBio Pharma Inc's logo look like?
Complete history of Frank Mccormick stock trades at Aduro BioTech、Exelixis Inc、BridgeBio Pharma Inc、Olema Pharmaceuticals
BridgeBio Pharma Inc executives and stock owners
BridgeBio Pharma Inc executives and other stock owners filed with the SEC include:
-
Neil Kumar,
Chief Executive Officer, Director -
Charles Homcy,
Chairman of Pharmaceuticals, Lead Director -
Uma Sinha,
Chief Scientific Officer -
Brian Stephenson,
Chief Financial Officer -
Eric Aguiar,
Independent Director -
Ali Satvat,
Independent Director -
Jennifer Cook,
Independent Director -
Dr. Neil Kumar Ph.D.,
Co-Founder, CEO & Director -
Dr. Brian C. Stephenson C.F.A., Ph.D.,
CFO, Sec. & Principal Accounting Officer -
James Momtazee,
Independent Director -
Richard Scheller,
Chairman of Research and Development, Director -
Dr. Michael Thomas Henderson M.D.,
Chief Bus. Officer -
Dr. Charles J. Homcy M.D.,
Chairman of Pharmaceuticals & Lead Director -
Dr. Richard H. Scheller Ph.D.,
Chairman of R&D and Director -
Dr. Cameron Turtle DPHIL, Ph.D.,
Chief Strategy Officer -
Randal Scott,
Independent Director -
Brenton Saunders,
Independent Director -
Andrew Lo,
Independent Director -
Ronald Daniels,
Independent Director -
Michael Henderson,
Chief Business Officer -
Cameron Turtle,
Senior Vice President - Portfolio Management and Corporate Development -
Frank Mccormick,
Chairman of Oncology -
Dr. Frank McCormick Ph.D.,
Chairman of Oncology -
Grace Rauh,
VP of Communications -
Dr. Uma Sinha Ph.D.,
Chief Scientific Officer -
Yi Ching Yau,
Chief Accounting Officer -
Genetic Disorder L.P.Kkr Ge...,
-
Management Holdings L.P.Kkr...,
-
Douglas A. Dachille,
-
Fred Hassan,
-
Global Performance Llc Viki...,
-
Global Investors Lp Viking ...,
-
Genetic Disorder L.P.Robert...,
-
Yi Ching Yau,
Chief Accounting Officer -
Brian M. Stolz,
Chief Operating Officer -
Hannah Valantine,
-
Brent L Saunders,
Director -
Andrea Ellis,
-
Global Investors Lp Viking ...,
-
Thomas Trimarchi,
President and COO